Micro-Cap Earnings Season: SES AI, AmpliTech, Nexstim and Asiafin Report Broad Q2 Growth

The Quick Take

• SES AI revenue surged 40% YoY with expanding drone capacity as commercial UAV adoption accelerates
• Nexstim posted 144% Research revenue growth with an 80% gross margin and positive EBITDA
• AmpliTech delivered 51% sequential revenue growth but withheld $50M annual guidance reaffirmation
• Asiafin Holdings reported strong profitability with a 50.1% gross margin and positive net income

Synthesized from 18 sources.

The second quarter 2026 micro-cap earnings season produced a cluster of strong results from companies spanning advanced materials, medical devices, defense electronics, and financial technology. SES AI Corporation, the next-generation battery developer for aerospace and drone applications, reported 40% year-over-year revenue growth with expanding drone capacity utilization — a signal that commercial drone propulsion customers are increasing orders as the commercial UAV market scales globally. AmpliTech Group, a designer of RF amplifiers and wireless infrastructure components, posted 51% sequential revenue growth with margin expansion, though management withheld reaffirmation of its $50 million annual revenue guidance due to customer deployment timing uncertainty.

Nexstim Oyj, a Finnish medical technology company specializing in navigated brain stimulation devices, reported Q2 revenue growth of 16% with its Research and Neuroscience segment surging 144% year-over-year. An 80% gross margin and positive EBITDA position Nexstim as an unusually profitable small-cap medtech company at its current commercialization stage. Asiafin Holdings, an Asia-Pacific financial services company, demonstrated strong profitability discipline with a 50.1% gross margin and net income of $431 thousand — modest in absolute terms but significant as an indicator of cost structure maturity for a micro-cap fintech. Together, these results illustrate that micro-cap companies across technology, healthcare, and financial services are generating genuine top-line growth and profitability improvement in 2026.

The micro-cap earnings cohort warrants attention from growth-oriented investors, as several of these companies are operating in niche markets with limited sell-side coverage and potentially undervalued relative to their growth rates. SES AI's drone propulsion revenue trajectory is a direct proxy for the commercial UAV market's adoption cycle, projected to compound at 20-30% annually through 2030. AmpliTech's guidance uncertainty around the $50 million revenue target reflects customer-side deployment timing rather than demand cancellation, suggesting the revenue opportunity remains intact. Investors in micro-cap technology and medtech should monitor Q3 reports for evidence that growth rates sustain as commercial scaling continues.